Testing for RAS and BRAF mutations is essential because these results can help guide the selection of a chemotherapy regimen.[6,7] Conversion therapy is considered when systemic chemotherapy has a good response for initially unresectable colorectal cancer. The gene discussed is BRAF; the disease is colorectal cancer.